Page 9 - Text View News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation.  TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial May 5, 2021 GMT HELSINKI, Finland--(BUSINESS WIRE)--May 5, 2021-- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus. The trial is being performed in pat...

Share this article SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/ --  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2 a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA ® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112). 1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-relate...

There is particular interest in monoclonal antibody agents to determine whether their immune suppressive effects can reduce the immediate and long-term impact of COVID-19.